Patients with SF at fifth year, n = 84 | Patients without SF at fifth year, n = 23 | p Valuea | |
---|---|---|---|
Sociodemographic variables | |||
Female sex, number (%) of patients | 73 (86.9) | 22 (95.7) | 0.46 |
Age at baseline, yr (mean ± SD) | 36.1 ± 12.2 | 48.5 ± 13.6 | 0.000 |
Years of formal education (mean ± SD) | 11.3 ± 3.9 | 9.7 ± 4.2 | 0.09 |
Current smokers, number (%) of patients | 9 (10.7) | 0 (0) | 0.2 |
Disease characteristics at baselineb | |||
Disease duration, mo | 5.3 (3.8–7.5) | 3.8 (2.5–6.2) | 0.05 |
Patients with RF, n (%) | 69 (82.1) | 19 (82.6) | 1 |
Patients with ACCP, n (%) | 72 (85.7) | 20 (87) | 1 |
DAS28 | 6 (4.9–6.9) | 6.8 (6–7.7) | 0.02 |
HAQ | 1.4 (0.8–2) | 2.1 (1.6–3) | 0.000 |
Patients with erosions, n (%) | 9 (10.7) | 2 (8.7) | 1 |
Number (%) of patients with ≥1 comorbidity | 65 (77.4) | 20 (87) | 0.39 |
Number of comorbidities/patient | 1 (1–2) | 2 (1–2.8) | 0.2 |
Cumulative treatment characteristicsb | |||
Patients with corticosteroids, n (%) | 42 (50) | 16 (69.6) | 0.11 |
Number of DMARDs/patient | 2.3 (1.9-2.9) | 2.4 (2–3) | 0.44 |
Number (%) of patients with ≥1 non-persistence period | 57 (76.9) | 17 (73.9) | 0.8 |
Follow-up at first non-persistence period,c mo | 13 (1–31) | 13 (1–22) | 0.25 |
Persistence duration, mod | 42 (30–48) | 36 (12–48) | 0.08 |